Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation.
Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation.
J. Kochenderfer,M. Dudley,21 Authors,S. Rosenberg
2013 · DOI: 10.1182/blood-2013-08-519413
Blood · 551 Citations
TLDR
Results show for the first time that donor-derived allogeneic anti-CD19-CAR T cells can cause regression of B-cell malignancies resistant to standard DLIs without causing GVHD.